Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
Aerie Pharma (AERI) Received its Third Buy in a Row - Markets
12:43pm, Friday, 12'th Jun 2020
After Mizuho Securities and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy,
Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead
09:18am, Wednesday, 10'th Jun 2020
The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d
Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher
07:08am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M
What's Opthea eyeing now that it has two successful trials under its belt? - Stockhead
03:44am, Wednesday, 10'th Jun 2020
Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema
Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon
02:49am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
12:16am, Wednesday, 10'th Jun 2020
Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
11:30am, Thursday, 28'th May 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc
Haemonetics Co. (NYSE:HAE) Shares Bought by Acadian Asset Management LLC
09:28am, Wednesday, 27'th May 2020
Acadian Asset Management LLC lifted its holdings in Haemonetics Co. (NYSE:HAE) by 9.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)
Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development - ResearchAndMarkets.com
12:00am, Thursday, 21'st May 2020
The
Global Macular Edema Therapeutics Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025
01:29pm, Sunday, 03'rd May 2020
May 03, 2020 (CDN Newswire via Comtex) --
A recent comprehensive study titled Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and...
Kalvista Pharmaceuticals (NASDAQ:KALV) Downgraded by Zacks Investment Research to "Hold"
08:06am, Thursday, 30'th Apr 2020
Kalvista Pharmaceuticals (NASDAQ:KALV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According
Bank of New York Mellon Corp Has $623,000 Stock Holdings in Kalvista Pharmaceuticals Inc (NASDAQ:KALV)
08:48am, Tuesday, 28'th Apr 2020
Bank of New York Mellon Corp trimmed its position in Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exch
Have Insiders Been Buying KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares?
12:42pm, Monday, 20'th Apr 2020
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Needham Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
09:27am, Thursday, 16'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on KalVista Pharmaceuticals (
KALV
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Wednesday at
Wall Street Recommends Buying These 2 Falliing Knives
05:44pm, Monday, 13'th Apr 2020
Their low debt-equity ratio reduces the investment risk Continue reading...
